AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24897504 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic paracetamol treatment (24 hours starting at vaccination)
Number of subjects: 496
Study 24897504 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic paracetamol treatment (6 hours after vaccination)
Number of subjects: 496
Study 24897504 — intervention group
Group type: COMPARATOR
Intervention: Control group (no paracetamol)
Number of subjects: 496
Study 23415202 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential postoperative antibiotic therapy (i.v. and oral)
Number of subjects: 27
Study 23415202 — intervention group
Group type: COMPARATOR
Intervention: Conventional antibiotic treatment
Number of subjects: 27
Study 20047618 — intervention group
Group type: EXPERIMENTAL
Intervention: EC‐MPS (720 mg b.i.d.)
Number of subjects: 24
Study 20047618 — intervention group
Group type: EXPERIMENTAL
Intervention: MMF (1000 mg b.i.d.)
Number of subjects: 24
Study 20047618 — intervention group
Group type: COMPARATOR
Intervention: EC‐MPS
Number of subjects: 24
Study 20047618 — intervention group
Group type: COMPARATOR
Intervention: MMF
Number of subjects: 24
Study 18552164 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT device switched on
Number of subjects: 32
Study 18552164 — intervention group
Group type: COMPARATOR
Intervention: CRT device switched off
Number of subjects: 32
Study 16098774 — intervention group
Group type: EXPERIMENTAL
Intervention: Venous grafts
Number of subjects: 2690
Study 16098774 — intervention group
Group type: COMPARATOR
Intervention: Prosthetic grafts
Number of subjects: 2690
Study 11871950 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 microg x kg(‐1) remifentanil
Number of subjects: 62
Study 11871950 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 62
Study 10443648 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam (0.02 mg/kg, administered orally at 0700 h)
Number of subjects: 6
Study 10443648 — intervention group
Group type: COMPARATOR
Intervention: Metyrapone (0.04 g/kg, administered orally at 2300 h the night before)
Number of subjects: 6
Study 10443648 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam after Metyrapone
Number of subjects: 6
Study 7809832 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide
Number of subjects: 218
Study 7809832 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 218
Study 1969248 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 0
Study 1969248 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 0
Study 1969248 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 373906 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapy A (2 AV followed by 2 CMF)
Number of subjects: 110
Study 373906 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapy B (2 CMF followed by 2 AV)
Number of subjects: 110
Study 373906 — intervention group
Group type: COMPARATOR
Intervention: Control (not applicable)
Number of subjects: 110
Study 30772980 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimulation combined with biofeedback therapy (6 weeks)
Number of subjects: 50
Study 30772980 — intervention group
Group type: COMPARATOR
Intervention: Control group (recovered spontaneously)
Number of subjects: 50
Study 30772980 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimulation combined with biofeedback therapy
Number of subjects: 50
Study 28758341 — intervention group
Group type: EXPERIMENTAL
Intervention: Belatacept more-intensive
Number of subjects: 218
Study 28758341 — intervention group
Group type: EXPERIMENTAL
Intervention: Belatacept less-intensive
Number of subjects: 218
Study 28758341 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine
Number of subjects: 218
Study 28758341 — intervention group
Group type: EXPERIMENTAL
Intervention: Belatacept 4-weekly
Number of subjects: 218
Study 28758341 — intervention group
Group type: EXPERIMENTAL
Intervention: Belatacept 8-weekly
Number of subjects: 218
Study 25281475 — intervention group
Group type: EXPERIMENTAL
Intervention: iTBS
Number of subjects: 30
Study 25281475 — intervention group
Group type: EXPERIMENTAL
Intervention: cTBS
Number of subjects: 30
Study 25281475 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 23446897 — intervention group
Group type: EXPERIMENTAL
Intervention: Choline intake of 930 mg/d
Number of subjects: 47
Study 23446897 — intervention group
Group type: EXPERIMENTAL
Intervention: Choline intake of 480 mg/d
Number of subjects: 47
Study 23446897 — intervention group
Group type: EXPERIMENTAL
Intervention: Choline intake (both 480 mg/d and 930 mg/d)
Number of subjects: 47
Study 23446897 — intervention group
Group type: COMPARATOR
Intervention: Baseline comparison
Number of subjects: 47
Study 20876346 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision Aid (DA)
Number of subjects: 214
Study 20876346 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 214
Study 19013258 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine collagen treatment at 15 months
Number of subjects: 0
Study 19013258 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16963174 — intervention group
Group type: EXPERIMENTAL
Intervention: Desogestrel (75 microg/d)
Number of subjects: 40
Study 16963174 — intervention group
Group type: COMPARATOR
Intervention: Combined oral contraceptive (ethinyl estradiol 20 microg plus desogestrel 150 microg)
Number of subjects: 40
Study 15470992 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental Product E (10% carbamide peroxide gel containing potassium nitrate and sodium fluoride)
Number of subjects: 22
Study 11471410 — intervention group
Group type: EXPERIMENTAL
Intervention: ACL reconstruction using autogenous, TETRA‐L3 augmented bone tendon bone graft
Number of subjects: 80
Study 9428487 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy
Number of subjects: 5156
Study 9428487 — intervention group
Group type: COMPARATOR
Intervention: Single agent chemotherapy (platinum analogue or vinorelbine)
Number of subjects: 5156
Study 7979615 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler perfusion index (DPI)
Number of subjects: 90
Study 7979615 — intervention group
Group type: COMPARATOR
Intervention: Intraoperative ultrasound
Number of subjects: 90
Study 2721107 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingually administered buprenorphine (1, 2, and 4 mg)
Number of subjects: 10
Study 2721107 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneously administered buprenorphine (1 and 2 mg)
Number of subjects: 10
Study 2721107 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 1026545 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefadroxil, 0.6-1.8 g per day, given twice or three times daily
Number of subjects: 36
Study 1026545 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefadroxil
Number of subjects: 36
Study 30021408 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 150 mg
Number of subjects: 70
Study 30021408 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 28796313 — intervention group
Group type: EXPERIMENTAL
Intervention: Lean mass
Number of subjects: 454
Study 28796313 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine kinase (CK)
Number of subjects: 454
Study 28796313 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat mass
Number of subjects: 454
Study 26294136 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextromethorphan (DXM) 120 mg
Number of subjects: 40
Study 26294136 — intervention group
Group type: COMPARATOR
Intervention: Guaifenesin 400 mg
Number of subjects: 40
Study 22641581 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 once a month (group D3M)
Number of subjects: 39
Study 22641581 — intervention group
Group type: COMPARATOR
Intervention: Vitamin D2 once a month (group D2M)
Number of subjects: 39
Study 22641581 — intervention group
Group type: COMPARATOR
Intervention: Vitamin D2 in small fractionated doses at each HD session, 3 times per week (group D2S)
Number of subjects: 39
Study 21448304 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary supplement containing 13 mg p-synephrine and 176 mg caffeine
Number of subjects: 23
Study 21448304 — intervention group
Group type: COMPARATOR
Intervention: Non-caloric placebo
Number of subjects: 23
Study 21448304 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary supplement containing caffeine and p-synephrine
Number of subjects: 23
Study 19653920 — intervention group
Group type: EXPERIMENTAL
Intervention: Encapsulated FeSO4 (10 mg Fe and 150 microg iodine)
Number of subjects: 279
Study 19653920 — intervention group
Group type: EXPERIMENTAL
Intervention: NutraFine RS (20 mg Fe)
Number of subjects: 279
Study 19653920 — intervention group
Group type: COMPARATOR
Intervention: Control group (no fortification Fe)
Number of subjects: 279
Study 17468120 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose aspirin (100 mg on alternate days)
Number of subjects: 6377
Study 17468120 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6377
Study 14695720 — intervention group
Group type: EXPERIMENTAL
Intervention: GEB-guided technique
Number of subjects: 240
Study 14695720 — intervention group
Group type: COMPARATOR
Intervention: Digital technique
Number of subjects: 240
Study 14695720 — intervention group
Group type: COMPARATOR
Intervention: Introducer tool (IT) technique
Number of subjects: 240
Study 11343977 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus (Tac) in combination with mycophenolate mofetil (MMF) and steroids
Number of subjects: 50
Study 11343977 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine (CsA) in combination with mycophenolate mofetil (MMF) and steroids
Number of subjects: 50
Study 9156357 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoprenaline infusion (0.1, 0.2, 0.4, 0.75, and 1.5 micrograms/min for 15 min each)
Number of subjects: 10
Study 9156357 — intervention group
Group type: COMPARATOR
Intervention: Saline control infusion
Number of subjects: 10
Study 7701049 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous (i.v.) bolus injection of 6 mg benperidol
Number of subjects: 13
Study 7701049 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration as liquid
Number of subjects: 13
Study 7701049 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration as tablets
Number of subjects: 13
Study 3605732 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 5 micrograms X kg‐1 po
Number of subjects: 30
Study 3605732 — intervention group
Group type: COMPARATOR
Intervention: Diazepam 0.15 mg X kg‐1 po
Number of subjects: 30
Study 31720903 — intervention group
Group type: EXPERIMENTAL
Intervention: Calibration sample (N = 2071)
Number of subjects: 3120
Study 31720903 — intervention group
Group type: EXPERIMENTAL
Intervention: Validation sample (N = 1049)
Number of subjects: 3120
Study 31720903 — intervention group
Group type: EXPERIMENTAL
Intervention: Factor 1
Number of subjects: 3120
Study 31720903 — intervention group
Group type: EXPERIMENTAL
Intervention: Factor 2
Number of subjects: 3120
Study 29135330 — intervention group
Group type: EXPERIMENTAL
Intervention: miLivingStory
Number of subjects: 86
Study 29135330 — intervention group
Group type: COMPARATOR
Intervention: miOwnResources
Number of subjects: 86
Study 26699594 — intervention group
Group type: EXPERIMENTAL
Intervention: Fondaparinux
Number of subjects: 78
Study 26699594 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study 25898782 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled sedation (PCS) with propofol (5 mg bolus doses as needed)
Number of subjects: 281
Study 25898782 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse anesthetist-controlled sedation (ACS) with 2-8 mg/kg/h of propofol
Number of subjects: 281
Study 25898782 — intervention group
Group type: COMPARATOR
Intervention: Midazolam (control group) with 2-3 mg for induction and additional 1 mg if required
Number of subjects: 281
Study 23611222 — intervention group
Group type: EXPERIMENTAL
Intervention: HHT + ATRA + AS2O3
Number of subjects: 35
Study 23611222 — intervention group
Group type: COMPARATOR
Intervention: Idarubicin (IDA) + ATRA + AS2O3
Number of subjects: 35
Study 20510971 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquatic resistance training (n=26)
Number of subjects: 50
Study 20510971 — intervention group
Group type: COMPARATOR
Intervention: No intervention (n=24)
Number of subjects: 50
Study 18752856 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropack (absorbable hyaluronic acid packing material)
Number of subjects: 60
Study 18752856 — intervention group
Group type: COMPARATOR
Intervention: Unpacked sinuses
Number of subjects: 60
Study 17217818 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-day sodium phosphate bowel preparation
Number of subjects: 40
Study 17217818 — intervention group
Group type: COMPARATOR
Intervention: 3-day magnesium sulfate bowel preparation
Number of subjects: 40
Study 17217818 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 12959742 — intervention group
Group type: EXPERIMENTAL
Intervention: Endogenous digoxin synthesis
Number of subjects: 15
Study 12959742 — intervention group
Group type: EXPERIMENTAL
Intervention: Tryptophan catabolites
Number of subjects: 15
Study 12959742 — intervention group
Group type: EXPERIMENTAL
Intervention: Tyrosine catabolites
Number of subjects: 15
Study 12959742 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholesterol:phospholipid ratio
Number of subjects: 15
Study 12959742 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycoconjugate levels of RBC membrane
Number of subjects: 15
Study 12959742 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune activation
Number of subjects: 15
Study 12959742 — intervention group
Group type: EXPERIMENTAL
Intervention: Free radical generation
Number of subjects: 15
Study 12959742 — intervention group
Group type: EXPERIMENTAL
Intervention: Altered glycoconjugate metabolism
Number of subjects: 15
Study 14746855 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical drains following radical hysterectomy
Number of subjects: 234
Study 10198901 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg/kg/day x 5 days (Group I)
Number of subjects: 59
Study 10198901 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg/kg/day x 5 days (Group II)
Number of subjects: 59
Study 10198901 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg/kg/day x 5 days (Group III)
Number of subjects: 59
Study 10198901 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg/kg/day x 5 days (second treatment for Group I)
Number of subjects: 59
Study 10198901 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg/kg/day x 5 days (second treatment for Group II)
Number of subjects: 59
Study 10198901 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse reactions (all groups)
Number of subjects: 59
Study 7774238 — intervention group
Group type: EXPERIMENTAL
Intervention: E5 (2 mg/kg/day by intravenous infusion 24 hrs apart)
Number of subjects: 847
Study 7774238 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 847
Study 2195062 — intervention group
Group type: EXPERIMENTAL
Intervention: hGH alone (0.1 mg.kg‐1.d‐1)
Number of subjects: 32
Study 2195062 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone alone (0.8 mg.kg‐1.d‐1)
Number of subjects: 32
Study 2195062 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone plus hGH
Number of subjects: 32
Study 2195062 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 669246 — intervention group
Group type: EXPERIMENTAL
Intervention: Powder
Number of subjects: 0
Study 669246 — intervention group
Group type: EXPERIMENTAL
Intervention: Ointment
Number of subjects: 0
Study 669246 — intervention group
Group type: COMPARATOR
Intervention: Nothing
Number of subjects: 0
Study 31042015 — intervention group
Group type: EXPERIMENTAL
Intervention: Early closure (EC) of ileostomy at 30 days after creation
Number of subjects: 86
Study 31042015 — intervention group
Group type: COMPARATOR
Intervention: Standard closure (SC) of ileostomy at 90 days after creation
Number of subjects: 86
Study 31042015 — intervention group
Group type: EXPERIMENTAL
Intervention: Early closure (EC) of ileostomy
Number of subjects: 86
Study 27986344 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation therapy (RT) to the lung with doses of 50 to 60 Gy in 10-Gy increments.
Number of subjects: 50
Study 27986344 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation therapy (RT) to the left lung.
Number of subjects: 50
Study 25824533 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure and response prevention (EX/RP) therapy
Number of subjects: 40
Study 23622121 — intervention group
Group type: EXPERIMENTAL
Intervention: Ragweed AIT 1.5 Amb a 1-U
Number of subjects: 784
Study 23622121 — intervention group
Group type: EXPERIMENTAL
Intervention: Ragweed AIT 6 Amb a 1-U
Number of subjects: 784
Study 23622121 — intervention group
Group type: EXPERIMENTAL
Intervention: Ragweed AIT 12 Amb a 1-U
Number of subjects: 784
Study 23622121 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 784
Study 21199963 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-solving therapy (PST)
Number of subjects: 221
Study 21199963 — intervention group
Group type: COMPARATOR
Intervention: Supportive therapy (ST)
Number of subjects: 221
Study 19847184 — intervention group
Group type: EXPERIMENTAL
Intervention: Right-side injection of 60 mg papaverine
Number of subjects: 60
Study 19847184 — intervention group
Group type: EXPERIMENTAL
Intervention: Left-side injection of 60 mg papaverine
Number of subjects: 60
Study 19847184 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral injection of 30 mg papaverine into each side
Number of subjects: 60
Study 17075239 — intervention group
Group type: EXPERIMENTAL
Intervention: Gambling Task (GT) performance in obese subjects (OS)
Number of subjects: 20
Study 17075239 — intervention group
Group type: COMPARATOR
Intervention: Gambling Task (GT) performance in normal-weight subjects (NWS)
Number of subjects: 20
Study 15011926 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized letter plus stage-targeted booklets
Number of subjects: 719
Study 15011926 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 719
Study 11727293 — intervention group
Group type: EXPERIMENTAL
Intervention: High involvement scenario
Number of subjects: 256
Study 11727293 — intervention group
Group type: COMPARATOR
Intervention: Low involvement scenario
Number of subjects: 256
Study 9406296 — intervention group
Group type: EXPERIMENTAL
Intervention: Antegrade cold blood cardioplegia
Number of subjects: 44
Study 9406296 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrograde cold blood cardioplegia
Number of subjects: 44
Study 9406296 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined antegrade-retrograde cold blood cardioplegia
Number of subjects: 44
Study 8427167 — intervention group
Group type: EXPERIMENTAL
Intervention: Anistreplase (30 U bolus over 5 minutes)
Number of subjects: 175
Study 8427167 — intervention group
Group type: COMPARATOR
Intervention: Streptokinase (1.5 million U over 60 minutes)
Number of subjects: 175
Study 31378980 — intervention group
Group type: EXPERIMENTAL
Intervention: Small-quantity lipid-based nutrient supplements (LNS-LNS)
Number of subjects: 1552
Study 31378980 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron and folic acid (IFA) and children received LNS (IFA-LNS)
Number of subjects: 1552
Study 31378980 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron and folic acid (IFA) and children received micronutrient powder (MNP) (IFA-MNP)
Number of subjects: 1552
Study 31378980 — intervention group
Group type: COMPARATOR
Intervention: Iron and folic acid (IFA) and children received no supplements (IFA-Control)
Number of subjects: 1552
Study 29973375 — intervention group
Group type: EXPERIMENTAL
Intervention: GX-H9 (0.1 mg/kg weekly)
Number of subjects: 45
Study 29973375 — intervention group
Group type: EXPERIMENTAL
Intervention: GX-H9 (0.3 mg/kg EOW)
Number of subjects: 45
Study 29973375 — intervention group
Group type: EXPERIMENTAL
Intervention: GX-H9 (0.2 mg/kg EOW)
Number of subjects: 45
Study 29973375 — intervention group
Group type: COMPARATOR
Intervention: Genotropin (6 µg/kg)
Number of subjects: 45
Study 27512639 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 % ropivacaine (group R, n = 53)
Number of subjects: 106
Study 27512639 — intervention group
Group type: COMPARATOR
Intervention: 0.9 % normal saline (group C, n = 53)
Number of subjects: 106
Study 23733348 — intervention group
Group type: EXPERIMENTAL
Intervention: Theory-based invitation letter
Number of subjects: 375
Study 23733348 — intervention group
Group type: COMPARATOR
Intervention: Standard invitation letter
Number of subjects: 375
Study 23733348 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational leaflet
Number of subjects: 375
Study 23902589 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted advance notification and standard invitation
Number of subjects: 9200
Study 23902589 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard advance notification and targeted invitation
Number of subjects: 9200
Study 23902589 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted advance notification and targeted invitation
Number of subjects: 9200
Study 23902589 — intervention group
Group type: COMPARATOR
Intervention: Standard advance notification and standard invitation
Number of subjects: 9200
Study 21038649 — intervention group
Group type: EXPERIMENTAL
Intervention: Qishen Huoxue Granules (QHG) + Continuous Renal Replacement Therapy (CRRT)
Number of subjects: 52
Study 21038649 — intervention group
Group type: COMPARATOR
Intervention: Continuous Renal Replacement Therapy (CRRT)
Number of subjects: 52
Study 18486352 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise-related activities
Number of subjects: 187
Study 18486352 — intervention group
Group type: COMPARATOR
Intervention: No exercise-related activities
Number of subjects: 187
Study 17058826 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganneng Dripping Pill (GDP)
Number of subjects: 84
Study 17058826 — intervention group
Group type: COMPARATOR
Intervention: Lamivudine (Control)
Number of subjects: 84
Study 12837560 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (TPM) 200 mg administered rectally
Number of subjects: 12
Study 12837560 — intervention group
Group type: COMPARATOR
Intervention: Topiramate (TPM) 100 mg administered orally
Number of subjects: 12
Study 12837560 — intervention group
Group type: COMPARATOR
Intervention: Topiramate (TPM) 200 mg administered orally
Number of subjects: 12